NCT02561234View on ClinicalTrials.gov

A Multiple Dose, Dose Escalation Trial of AEB1102 in Patients With Advanced Solid Tumors

PHASE1/PHASE2CompletedINTERVENTIONAL
Enrollment

98

Participants

Timeline

Start Date

October 31, 2015

Primary Completion Date

May 31, 2019

Study Completion Date

May 31, 2019

Conditions
Advanced Cancers
Interventions
DRUG

Co-ArgI-PEG

Administered IV

Trial Locations (11)

10032

Columbia University, New York

15232

University of Pittsburgh, Pittsburgh

32763

Research Center: Mid Florida Hematology/Oncology Centers, Orange City

80045

University of Colorado, Aurora

85258

Pinnacle Research, Phoenix

90024

UCLA, Los Angeles

93110

Washington University, St Louis

97213

Providence Cancer Center, Portland

02114

Dana Farber, Boston

Massachusetts General, Boston

75390-8852

UTSW, Dallas

Sponsors
All Listed Sponsors
lead

Aeglea Biotherapeutics

INDUSTRY

NCT02561234 - A Multiple Dose, Dose Escalation Trial of AEB1102 in Patients With Advanced Solid Tumors | Biotech Hunter | Biotech Hunter